Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced that Chief Executive Officer Mark Baker will present on Thursday, June 5th, at 10:00 AM EDT at the Jefferies Global Healthcare Conference in New York City.Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) weekly performance is -14.89%. On last trading day company shares ended up $3.43. Analysts mean target price for the company is $9.50. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) distance from 50-day simple moving average is -8.47%.
Transcept Pharmaceuticals, Inc. (NASDAQ:TSPT) will begin trading ex-dividend on June 04, 2014. A cash dividend payment of $1.33 per share is scheduled to be paid on June 03, 2014. Transcept Pharmaceuticals Inc (NASDAQ:TSPT) shares advanced 10.16% in last trading session and ended the day on $2.06. TSPT its return on assets is -34.00%. Transcept Pharmaceuticals Inc (NASDAQ:TSPT) quarterly performance is -38.32%.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer, will be presenting at the Goldman Sachs 35th Annual Global Healthcare Conference on June 11, 2014 at 1:20pm PT at Terranea in Rancho Palos Verdes, California.Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares moved down -5.81% in last trading session and was closed at $33.55, while trading in range of $32.36-$36.00. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) year to date performance is -20.59%.
Ruthigen Inc (NASDAQ:RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, is pleased to announce the distribution of a letter from Hojabr Alimi, the Company’s Chairman, Chief Executive Officer and Chief Science Officer, to its stockholders on Form 8-K on June 3, 2014. Ruthigen Inc (NASDAQ:RTGN) ended the last trading day at $6.27. Company weekly volatility is calculated as 3.76%. Ruthigen Inc (NASDAQ:RTGN) showed a positive weekly performance of 3.47%.
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced that Franklin C. Salisbury, Jr. has joined the Company’s Board of Directors.EntreMed Inc (NASDAQ:ENMD) weekly performance is -6.56%. On last trading day company shares ended up $1.71. Analysts mean target price for the company is $1.00. EntreMed Inc (NASDAQ:ENMD) distance from 50-day simple moving average is -7.11%.